Moderna (NASDAQ:MRNA) President Sells $8,601,885.60 in Stock

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) President Stephen Hoge sold 39,160 shares of the business’s stock in a transaction on Monday, November 16th. The stock was sold at an average price of $219.66, for a total value of $8,601,885.60. Following the completion of the transaction, the president directly owned 1,673,858 shares of the company’s stock, valued at approximately $367,679,648.28. The trade was a 2.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

  • On Tuesday, November 17th, Stephen Hoge sold 39,215 shares of Moderna stock. The stock was sold at an average price of $211.61, for a total value of $8,298,286.15.
  • On Thursday, October 15th, Stephen Hoge sold 39,145 shares of Moderna stock. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40.
  • On Wednesday, October 14th, Stephen Hoge sold 39,224 shares of Moderna stock. The shares were sold at an average price of $213.48, for a total value of $8,373,539.52.
  • On Monday, September 14th, Stephen Hoge sold 40,294 shares of Moderna stock. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22.
  • On Tuesday, September 15th, Stephen Hoge sold 40,281 shares of Moderna stock. The shares were sold at an average price of $146.07, for a total transaction of $5,883,845.67.

Moderna Stock Down 2.6%

NASDAQ:MRNA opened at $194.18 on Friday. The company’s 50-day simple moving average is $207.87 and its 200-day simple moving average is $100.37. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $280.80.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings data on Friday, November 6th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. Moderna’s revenue was up 29.2% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.51) EPS. On average, equities analysts forecast that Moderna, Inc. will post -5.40 EPS for the current year.

Hedge Funds Weigh In On Moderna

Institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in shares of Moderna in the 2nd quarter valued at about $2,142,877,000. Theleme Partners LLP purchased a new stake in shares of Moderna during the second quarter worth approximately $564,272,000. Merck & Co. Inc. acquired a new stake in Moderna in the second quarter valued at approximately $161,642,545. Bamco Inc. NY acquired a new position in Moderna during the 2nd quarter worth approximately $139,317,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Moderna in the 2nd quarter valued at approximately $119,168,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Key Moderna News

Here’s some of the latest news about MRNA:

  • Positive Sentiment: A report says Morgan Stanley sees potential for substantial share-price appreciation, offering a more optimistic view amid recent volatility. Article: Morgan Stanley Forecasts Strong Price Appreciation
  • Negative Sentiment: President Stephen Hoge sold shares in transactions reported for November 16 and 17, and coverage noted the stock fell below its 50-day moving average. The sales were made under a pre-arranged Rule 10b5-1 plan, so they do not necessarily signal a change in his view of the company, but they may add to near-term selling pressure. Article: Moderna President Sells Shares
  • Neutral Sentiment: Bireme Capital disclosed that it sold its Moderna position after the stock’s rally. That reflects one manager’s portfolio decision, rather than a company announcement. Article: Bireme Capital Sold Moderna

Analysts Set New Price Targets

MRNA has been the subject of a number of research reports. William Blair cut Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Piper Sandler reaffirmed an “overweight” rating and set a $305.00 target price (up from $230.00) on shares of Moderna in a research note on Monday, November 9th. The Goldman Sachs Group boosted their price objective on Moderna from $137.00 to $195.00 and gave the stock a “neutral” rating in a research note on Monday, November 9th. Wolfe Research raised Moderna from an “underperform” rating to a “peer perform” rating in a research note on Tuesday, August 25th. Finally, Barclays upped their target price on shares of Moderna from $48.00 to $125.00 and gave the company an “equal weight” rating in a research report on Monday, August 24th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $120.25.

Check Out Our Latest Stock Report on MRNA

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Featured Articles

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.